Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersHematology & Oncology Physician in Mountain View, CA
NPI: 1194941104Primary Practice Location
Mountain View Center
701 E El Camino Real, Mountain View, CA
Primary Employer
Palo Alto Medial Foundation
sutterhealth.org
HQ Phone
Get M.D. Derrick's Phone Numberphone_androidMobile
Get M.D. Derrick's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
2003 - 2027
American Board of Internal Medicine
Medical Oncology
David Geffen School of Medicine at UCLA
medschool.ucla.edu
Medical School
Until 2001
UCSF School of Medicine
medschool.ucsf.edu
Fellowship • Hematology and Medical Oncology
2004 - 2007
UCLA David Geffen School of Medicine/UCLA Medical Center
Residency • Internal Medicine
2001 - 2004
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 276 | 372 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 248 | 732 |
| 3 | J7050Infusion, normal saline solution , 250 cc | 162 | 277 |
| 4 | 96365Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | 145 | 338 |
| 5 | 96413Infusion of chemotherapy into a vein up to 1 hour | 123 | 343 |
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strate...
Authors: Andrew H. Ko, Elizabeth Dito, Brian Schillinger, Alan P. Venook, Zhidong Xu
Authors: Emily Bergsland, Alan Venook, Andrew Ko
Journal: Pancreas
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
Authors: Emily Bergsland, Alan Venook, Andrew Ko
Publication Date: 2008-04
